Hear from A/Prof. Kerry Hitos, Director of the Westmead Research Centre for Evaluation of Surgical Outcomes, University of Sydney, Westmead Hospital.
A/Prof. Kerry Hitos describes why Australian researchers have excellent reputations.
An individualised patient-centered approach for assessing VTE risk in medical patients is recommended by A/Prof. Kerry Hitos.
A/Prof. Kerry Hitos reviews the new ACSQH Clinical Care Standards and recommends practices that could see 100% of patients appropriately prophylaxed against VTE.
VTE = venous thromboembolism.
Date of preparation: March 2019. SM_SAN980. SAANZ.ENO.19.01.0069
*Clexane Safety Lock as an automatic safety lock system.
Further information is available on request from Sanofi.
.png?h=50&hash=1FAD9AA89BECA626449B1498364778611BE7C926&la=en)
PBS Information: CLEXANE®. General Benefit Antithrombotic agent. Refer to PBS schedule for full information.CLEXANE® with Automatic Safety Lock System. Refer to PBS schedule for full information. CLEXANE® FORTE. This product is not listed on the PBS.
Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.
sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.
Receive future issues of Anticoagulation Matters, compiled specifically for you.
Access patient information and resources on VTE and Clexane®.